Ms Anand has represented clients before the Ontario Superior Court and Federal Court of Canada in matters related to all aspects of intellectual property. Her practice focuses primarily on patent litigation related to various areas of technology, including pharmaceuticals, telecommunications and mechanical inventions. Ms Anand is a strategic, creative and fearless advocate who offers her clients comprehensive advice on Canadian and multi-jurisdictional litigation.

A scientist-turned-litigator, Ms Anand completed a PhD in molecular biology, genetics and cancer at McMaster University prior to obtaining her law degree at the University of Toronto. She has since taken a particular interest in biologic drugs and the pharmaceutical industry. In addition to patent litigation in the pharmaceutical space, she has also advised pharmaceutical clients on IP and litigation strategy, and on regulatory matters with Health Canada.

Ms Anand is also active in the local legal community. She is co-chair of the Canadian Bar Association’s diversity and inclusion committee, a board member of Neighbourhood Legal Services, a local community legal clinic, and a frequent volunteer in the legal community judging moots, where she coaches mooters and mentors young lawyers.


University of Toronto, Faculty of Law, Toronto, Ontario, Canada
  • J.D. - 2008
McMaster University, Faculty of Molecular Biology, Genetics and Cancer
  • Ph.D. - 2006
Acadia University, Faculty of Biology
  • B.Sc. - 1999


Published Works

  • Kristin Wall and Nisha Anand: "Recent Trends in Canadian Biologics Patent Litigation" FDLI Update, 2014
  • Heller, D. & Anand, N. "Functional Pharma Claim Flawed, Finds Federal Court of Canada", APLF IP Law Bugle, 2010
  • Thornton S, Anand N, Purcell D, Lee J. (2003) Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. Journal of Molecular Medicine 81(9): 536-48, 2003
  • Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, Collins C, Gray JW, Diebold J, Demetrick DJ, Lee JM. (2002) Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nature Genetics. Jul; 31(3): 301-5., 2002

Representative Cases

  • Corlac Inc. et al. v. Weatherford Canada Ltd. et al., 2010 FC 602
  • Safe Gaming System Inc. v. Atlantic Lottery Corporation et al., (T-1043-12)
  • Gilead Sciences, Inc. et al. v. Teva Canada Limited et al., 2013 FC 1270
  • Gilead Sciences, Inc. et al. v. Teva Canada Limited et al., 2013 FC 1272
  • Wi-LAN Inc. and Quarterhill Inc. v. TELUS Communications Inc. et al., (T-301-16), BellMobility Inc., (T-303-16), Rogers Communications Canada Inc., (T-304-16)
  • Pliteq Inc. v. Wilrep Ltd., (T-554-16)
  • Pliteq Inc. v. Ecore International, Inc. et al., (T-875-16)
  • Gilead Sciences, Inc. et al. v. Apotex Inc. et al., 2016 FC 856
  • Wi-LAN Inc. v. LG Electronics et al., (T-1349-17)
  • Pliteq Inc. v. Sof Surfaces Inc., (CV-18-00611575-000)
  • Pliteq Inc. v. Ecore International Inc. et al., (T-365-20)
  • Gilead Sciences, Inc. v. ViiV Healthcare Company et al., 2020 FC 486
  • Gilead Sciences, Inc. v. ViiV Healthcare Company et al., 2021 FCA 122

Professional Associations and Memberships

  • Intellectual Property Institute of Canada
  • Toronto Intellectual Property Group
  • The Advocates’ Society
  • Canadian Bar Association
  • Ontario Bar Association